PMID- 23683069
OWN - NLM
STAT- MEDLINE
DCOM- 20140527
LR  - 20220410
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Linking)
VI  - 15
IP  - 11
DP  - 2013 Nov
TI  - Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 
      elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, 
      double-blind, placebo-controlled, cross-over trial.
PG  - 1040-8
LID - 10.1111/dom.12133 [doi]
AB  - AIMS: Postprandial triglyceridaemia is a risk factor for cardiovascular disease 
      (CVD). This study investigated the effects of steady-state liraglutide 1.8 mg 
      versus placebo on postprandial plasma lipid concentrations after 3 weeks of 
      treatment in patients with type 2 diabetes mellitus (T2DM). METHODS: In a 
      cross-over trial, patients with T2DM (n = 20, 18-75 years, BMI 18.5-40 kg/m(2)) 
      were randomized to once-daily subcutaneous liraglutide (weekly dose escalation 
      from 0.6 to 1.8 mg) and placebo. After each 3-week period, a standardized 
      fat-rich meal was provided, and the effects of liraglutide on triglyceride 
      (primary endpoint AUC(0-8h)), apolipoprotein B48, non-esterified fatty acids, 
      glycaemic responses and gastric emptying were assessed. ClinicalTrials.gov ID: 
      NCT00993304. FUNDING: Novo Nordisk A/S. RESULTS: After 3 weeks, mean postprandial 
      triglyceride (AUC(0-8h) liraglutide/placebo treatment-ratio 0.72, 95% CI 
      [0.62-0.83], p = 0.0004) and apolipoprotein B48 (AUC(0-8h) ratio 0.65 
      [0.58-0.73], p < 0.0001) significantly decreased with liraglutide 1.8 mg versus 
      placebo, as did iAUC(0-8h) and C(max) (p < 0.001). No significant treatment 
      differences were observed for non-esterified fatty acids. Mean postprandial 
      glucose and glucagon AUC(0-8h) and C(max) were significantly reduced with 
      liraglutide versus placebo. Postprandial gastric emptying rate [assessed by 
      paracetamol absorption (liquid phase) and the (1)(3)C-octanoate breath test (solid 
      phase)] displayed no treatment differences. Mean low-density lipoprotein and 
      total cholesterol decreased significantly with liraglutide versus placebo. 
      CONCLUSIONS: Liraglutide treatment in patients with T2DM significantly reduced 
      postprandial excursions of triglyceride and apolipoprotein B48 after a fat-rich 
      meal, independently of gastric emptying. Results indicate liraglutide's potential 
      to reduce CVD risk via improvement of postprandial lipaemia.
CI  - (c) 2013 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & 
      Sons Ltd.
FAU - Hermansen, K
AU  - Hermansen K
AD  - Department of Medicine and Endocrinology MEA, Aarhus University Hospital, Aarhus, 
      Denmark.
FAU - Baekdal, T A
AU  - Baekdal TA
FAU - During, M
AU  - During M
FAU - Pietraszek, A
AU  - Pietraszek A
FAU - Mortensen, L S
AU  - Mortensen LS
FAU - Jorgensen, H
AU  - Jorgensen H
FAU - Flint, A
AU  - Flint A
LA  - eng
SI  - ClinicalTrials.gov/NCT00993304
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20130611
PL  - England
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Hypolipidemic Agents)
RN  - 0 (Lipids)
RN  - 839I73S42A (Liraglutide)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
SB  - IM
MH  - Aged
MH  - Body Mass Index
MH  - Cardiovascular Diseases/complications/epidemiology/*prevention & control
MH  - Cross-Over Studies
MH  - Denmark/epidemiology
MH  - Diabetes Mellitus, Type 2/blood/complications/*drug therapy
MH  - Diet, High-Fat/*adverse effects
MH  - Double-Blind Method
MH  - Female
MH  - Gastric Emptying/drug effects
MH  - Germany/epidemiology
MH  - Glucagon-Like Peptide 1/adverse effects/*analogs & 
      derivatives/blood/pharmacokinetics/therapeutic use
MH  - Half-Life
MH  - Humans
MH  - Hyperlipidemias/complications/etiology/*prevention & control
MH  - Hypoglycemic Agents/adverse effects/blood/pharmacokinetics/*therapeutic use
MH  - Hypolipidemic Agents/adverse effects/blood/pharmacokinetics/*therapeutic use
MH  - Lipids/blood
MH  - Liraglutide
MH  - Male
MH  - Middle Aged
MH  - Obesity/complications
MH  - Postprandial Period
MH  - Risk Factors
OTO - NOTNLM
OT  - GLP-1 analogue
OT  - antidiabetic drug
OT  - lipid-lowering therapy
OT  - phase I-II study
OT  - randomized trial
OT  - type II diabetes
EDAT- 2013/05/21 06:00
MHDA- 2014/05/28 06:00
CRDT- 2013/05/21 06:00
PHST- 2012/12/06 00:00 [received]
PHST- 2013/03/06 00:00 [revised]
PHST- 2013/05/14 00:00 [accepted]
PHST- 2013/05/21 06:00 [entrez]
PHST- 2013/05/21 06:00 [pubmed]
PHST- 2014/05/28 06:00 [medline]
AID - 10.1111/dom.12133 [doi]
PST - ppublish
SO  - Diabetes Obes Metab. 2013 Nov;15(11):1040-8. doi: 10.1111/dom.12133. Epub 2013 
      Jun 11.